2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2099

Elderly – Onset Sarcoidosis: a Single Center Comparative Study
Abstract Number: 2100

An International Consensus Exercise to Develop Candidate Items for Classification Criteria in Relapsing Polychondritis
Abstract Number: 2101

The Clinical Characteristics of IgG4 Related Disease in China: With 346 Cases Reported
Abstract Number: 2102

The Difference between International Criteria for BD (ICBD) and the BD Criteria of International Study Group (ISG) in Our Behcet’s Disease (BD) Patients Who Fulfilled Japanese BD Criteria
Abstract Number: 2103

Problems in the Diagnosis of Familial Mediterranean Fever in Turkey
Abstract Number: 2104

Exposure to Fine Particle Air Pollution and Anti-Nuclear Antibodies (ANA) in a Large Population-Based Sample
Abstract Number: 2105

Epidemiology of Interstitial Pneumonia with Autoimmune Features
Abstract Number: 2106

Immune-Related Adverse Events in Cancer Patients Treated with Immune Check Point Inhibitors: A Single Center Experience
Abstract Number: 2107

Therapeutic Response to Prednisone in Relation to Age in Polymyalgia Rheumatica: A Controlled Study
Abstract Number: 2108

Colchicine Treatment May be Protective Against Ventricular Arrhythmias in FMF Patients
Abstract Number: 2109

Hyperferritinemic Syndrome in a General Hospital
Abstract Number: 2110

Blood Group ”a“ Was Increased in FMF Patients and Blood Group ”0“ May be Associated with Colchicine Resistance
Abstract Number: 2111

Anti-N-Methyl-D-Aspartate Receptor Encephalitis – Expanding Our Understanding of the Clinical Needs of Pediatric Patients with This Complex Disorder
Abstract Number: 2112

Anti-TNFα Versus Rituximab in Refractory Peripheral Ulcerative Keratitis Associated to Rheumatic Diseases. Multicenter Study of 24 Patients
Abstract Number: 2113

Familial Mediterranean Fever in Chinese Adult Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].